Table 1.
Baseline characteristics and allocated treatments
| Variable | No. (%) (n=59) |
|---|---|
| Age, median (range, yr) | 63.0 (39.0–70.0) |
| Sex | |
| Male | 53 (89.8) |
| Female | 6 (10.2) |
| Body mass index, median (range, kg/m 2 ) | 24.3 (18.0–33.0) |
| ECOG performance score | |
| 0 | 8 (13.6) |
| 1 | 51 (86.4) |
| Clinical stage | |
| cT2 | 15 (25.4) |
| cT3 | 39 (66.1) |
| cT4a | 5 (8.5) |
| Biopsy differentiation | |
| High grade | 48 (81.4) |
| Low grade | 11 (18.6) |
| Tumor number | |
| Single | 41 (69.5) |
| Multiple | 18 (30.5) |
| NAC courses | |
| 2 | 18 (30.5) |
| 3 | 23 (39.0) |
| 4 | 18 (30.5) |
| NAC efficacy | |
| Definite responder (≤ T1) | 31 (52.5) |
| Incomplete responder | 26 (44.1) |
| Progressive disease | 2 (3.4) |
| Type of treatments | |
| NAC+TURBT+concurrent CRT | 25 (42.4) |
| NAC+TURBT | 2 (3.4) |
| NAC+TURBT+BCG instillation | 4 (6.8) |
| NAC+partial cystectomy+PLND | 4 (6.8) |
| NAC+RC+PLND | 20 (33.9) |
| NAC+second-line chemotherapy | 2 (3.4) |
| NAC+Chinese medicine | 2 (3.4) |
| Pathological stages of 20 RC patients | |
| pT1 | 1 (5.0) |
| pT2 | 5 (25.0) |
| pT3 | 12 (60.0) |
| pT4 | 2 (10.0) |
| pN0 | 14 (70.0) |
| pN1 | 6 (30.0) |
BCG, bacillus Calmette-Guerin; CRT, chemoradiotherapy; ECOG, Eastern Cooperative Oncology Group; NAC, neoadjuvant chemotherapy; PLND, pelvic lymphadenectomy; RC, radical cystectomy; TURBT, transurethral resection of bladder tumor.